Bruce Harmon has 40 years’ experience as CFO, director and/or audit chairman of public and private companies. Since 1993, he has operated his own consulting firm where he has served as an interim officer and/or director of various public companies during their growth stages. He has worked with a pharmaceutical company with the registration of an OTC product and the negotiation of the sale of the company to a large pharma company. He has taken 15 companies public on a contract basis.
Our team at Dale Biotech recognizes the need for the best scientific minds to come together to tackle the current health crisis related to COVID-19.
We are also committed to using our expertise with Rhamnolipids to develop an oral formulation which is not only efficacious but also cost effective. Our experience with Rhamnolipids and our early research with niclosamide, has led us to a unique formulation that has the potential to not only treat early cases of COVID-19 but also could be used for prophylaxis against COVID-19 and other future viral threats.
Please join us , as an investor or as follower, and support our efforts to combat this worldwide pandemic.